Statin Drug Use and the Risk of type 2 Diabetes Mellitus: Evidence-based Revision

• Autor(a) principal: Silva, Susana
• Data de Publicação: 2016
• Outros Autores: Monteiro, Nuno
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Revista Brasileira de Medicina de Família e Comunidade (Online)
• Texto Completo: https://www.rbmfc.org.br/rbmfc/article/view/1178
• topic: Diabetes Mellitus; Type 2. Hydroxymethylglutaryl-CoA Reductase Inhibitors. Incidence.; Diabetes Mellitus; Tipo 2. Inhibidores de Hidroximetilglutaril-CoA Reductasas. Incidencia; Diabetes Mellitus; Tipo 2. Inibidores de Hidroximetilglutaril-CoA Redutases. Incidência.; Diabetes Mellitus Type 2; Hydroxymethylglutaryl-CoA Reductase Inhibitors

Objective: To investigate the relationship between statin administration and the incidence of Diabetes Mellitus type 2. Methods: A systematic review of the literature was conducted using the following databases National Guidelines Clearinghouse, Cochrane Lybrary, Trip database, PubMed and MedLine using the MeSH terms “Diabetes Mellitus Type 2” and “Hydroxymethylglutaryl-CoA Reductase Inhibitors”. Systematic reviews, meta-analyses and randomized controlled trials analyzing the incidence of type 2 diabetes in statin users compared with placebo were included. Results: We selected 10 articles (1 meta-analysis and 9 randomized controlled trials). Evidence suggests that the use of statins is associated with an increased incidence of type 2 diabetes compared to placebo in most studies, especially at high dosages. Conclusion: The risk of incidence of type 2 diabetes should be considered especially when prescribing statins to patients with low cardiovascular risk (SOR A), despite the fact that selected studies present some limitations (heterogeneous methodology, and mostly observational).